Review
Copyright ©The Author(s) 2020.
World J Clin Oncol. Oct 24, 2020; 11(10): 809-835
Published online Oct 24, 2020. doi: 10.5306/wjco.v11.i10.809
Table 7 Empiric antibiotic therapy in high-risk patients with febrile neutropenia[40,54,55,79,83]
AntibiotherapyIndication
Antipseudomonal β-lactam agent (cefepime, ceftazidime)All patients with febrile neutropenia
OR
Carbapenem (meropenem or mipenem/cilastatin)Hemodynamic instability
OR
Piperacillin/tazobactam
OR
Novel cephalosporin/β-lactamase inhibitor (Ceftolozane/tazobactam or Ceftazidime/avibactam)
PLUS
Aminoglycosides (optional)
PLUS
Vancomycin
Vancomycin, linezolid or daptomycinSuspected catheter-related infections
Skin or soft-tissue infection
Risk of methicillin-resistant Staphylococcus aureus
Linezolid or daptomycinRisk of vancomycin-resistant Enterococcus spp.
CarbapenemRisk of extended-spectrum β-lactamase-producing gram negative bacteria
Polymyxin-colistin or tigecyclineRisk of Klebsiella pneumonia carbapenemase
Ciprofloxacin + clindamycinPenicillin-allergic patients
OR
Aztreonam + vancomycin
Trimethoprim/sulfamethoxazoleSuspected Pneumocystis pneumonia
Antifungal drugs (echinocandins, amphotericin B lipid-based formulations)Suspected invasive mycosis